Jens Hillengaß

Roswell Park Comprehensive Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 13 papers. Top paper: “CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab”.

CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab

Cytometry Part B Clinical Cytometry(2020)10.1002/cyto.b.21961

N/A

0DataRank · unranked

45 citations

Joseph D. Tario, Theresa Hahn, Jens Hillengaß, Philip L. McCarthy, Paul K. Wallace +1 more

Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Biology of Blood and Marrow Transplantation(2020)10.1016/j.bbmt.2020.06.011

N/A

0DataRank · unranked

6 citations

Alan Howard, David Avigan, Manisha Bhutani, Adam D. Cohen, Luciano J. Costa +22 more

The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma

Transplantation and Cellular Therapy(2021)10.1016/j.jtct.2021.05.027

N/A

0DataRank · unranked

3 citations

Nizar J. Bahlis, P. Leif Bergsagel, Manisha Bhutani, Niccolò Bolli, Carrie Brownstein +18 more

Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma

Nature Communications(2022)10.1038/s41467-022-28266-z

N/A

0DataRank · unranked

69 citations

Almuth Maria Anni Merz, Jie Wang, Lei Wei, Qiang Hu, Nicholas Hutson +19 more

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee

Blood Cancer Journal(2022)10.1038/s41408-022-00695-5

N/A

0DataRank · unranked

61 citations

Lawrence Baizer, Natalie S. Callander, Sergio Giralt, Jens Hillengaß, Boris Freidlin +11 more

Nutrition perceptions, needs and practices among patients with plasma cell disorders

Blood Cancer Journal(2022)10.1038/s41408-022-00666-w

N/A

0DataRank · unranked

16 citations

Nathan W. Sweeney, Mohammad Jafri, Andriy Derkach, Cynthia Chmielewski, Peter Adintori +18 more

Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma

Transplantation and Cellular Therapy(2022)10.1016/j.jtct.2022.05.019

N/A

0DataRank · unranked

1 citations

Fotis Asimakopoulos, Abdel Kareem Azab, Giada Bianchi, Manisha Bhutani, Leslie Crews +18 more

Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse population

Blood Advances(2023)10.1182/bloodadvances.2023011608

N/A

0DataRank · unranked

16 citations

Jens Hillengaß, Li Tang, Alexander M. Lesokhin, Ola Landgren, Saad Z. Usmani +4 more

Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse population

medRxiv(2023)10.1101/2023.09.05.23294947

N/A

0DataRank · unranked

2 citations

Jens Hillengaß, Li Tang, Alexander M. Lesokhin, Ola Landgren, Saad Z. Usmani +4 more

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

Journal of Clinical Oncology(2025)10.1200/jco-24-01893

N/A

0DataRank · unranked

142 citations

Faith E. Davies, Mehmet Samur, Jill Corre, Mattia D’Agostino, Martin Kaiser +41 more

Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma

Blood(2025)10.1182/blood.2025028963

N/A

0DataRank · unranked

8 citations

Qi Yan, Saeed Daneshmandi, Romain Lannes, Eriko Katsuta, Jee Eun Choi +14 more

Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.7503

N/A

0DataRank · unranked

10 citations

Jing Christine Ye, Jens Hillengaß, Douglas W. Sborov, James E. Hoffman, Benjamin Diamond +15 more

Rare case of pure red cell aplasia secondary to smoldering multiple myeloma successfully treated with daratumumab – case report and review of the literature

Annals of Hematology(2025)10.1007/s00277-025-06218-z

N/A

0DataRank · unranked

0 citations

Sawyer Bawek, Ian Lund, Sean T. Glenn, Steven Green, Hamza Hassan +3 more